Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. - Wikidata - awgldk - TriplyDB

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.

http://www.wikidata.org/entity/Q37644483

about

New targets for rapid antidepressant action.Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder.Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model.Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies.Addressing the unmet needs of current antidepressants: does neuroscience help or hinder clinical psychopharmacology research?Beyond Ketamine: New Approaches to the Development of Safer Antidepressants.Glutamatergic Modulators in Depression.Alternatives to ketamine in depression: state-of-the-art and future perspectives.Mechanisms of ketamine action as an antidepressant.Convergent Mechanisms Underlying Rapid Antidepressant Action.Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide.Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment

P2860

Q34507177-A297ED6F-6FB4-44FF-AB03-944C0E204F86 Q38802855-63559786-10D3-4B14-8FB4-5FBE0D26B4FA Q38990885-665A427C-1C6B-4A2B-B7B3-1E566AE6FC9B Q46259903-A1177DF8-931B-4982-8063-0DBDDE76CC86 Q47557944-1448D0DF-BD4E-41A3-8AAE-1DBEB5119C55 Q47805452-DDC55772-7CD0-4FA0-8DAB-B98C25B34680 Q47963007-24574661-4756-4E3E-99BD-2E62DC77A4AE Q49712849-16EA1D28-E74C-4214-A4F9-138576CF408A Q50355682-2BD72F03-949D-4842-9378-21E38427A6EB Q52658612-E4E4D3F2-2F8C-49B7-BB8B-253CF10C4D63 Q52667723-FAEB16E6-7F49-4A69-A10D-5AD3E96A63BE Q55089313-625A652D-65C7-475F-A804-E054FC400945 Q58213311-045FBB77-4EE3-48A6-B779-B0977E65856D Q58213868-535CDCA4-2D31-4247-87C7-6C522DCD6CFE

P2860

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.

http://www.wikidata.org/entity/Q37644483

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Adjunctive Lanicemine (AZD6765 ...... zed, Placebo-Controlled Study.

@en

Adjunctive Lanicemine (AZD6765 ...... zed, Placebo-Controlled Study.

@nl

type

label

Adjunctive Lanicemine (AZD6765 ...... zed, Placebo-Controlled Study.

@en

Adjunctive Lanicemine (AZD6765 ...... zed, Placebo-Controlled Study.

@nl

prefLabel

Adjunctive Lanicemine (AZD6765 ...... zed, Placebo-Controlled Study.

@en

Adjunctive Lanicemine (AZD6765 ...... zed, Placebo-Controlled Study.

@nl

P1433

Q37644483-80794B17-BF13-4620-BB8F-4C0312184CB1

P1476

Q37644483-46A90C5C-1A24-4769-851A-80C62C2BDB58

P2093

Q37644483-09D14296-4F5F-488C-8836-4DF3658D5CF9

Q37644483-0B8644BD-A134-4AEE-8B4D-1E98547FE3DF

Q37644483-0B90A14A-CC3A-4318-96B9-7737C2901C71

Q37644483-2E0FEBC2-ED69-40EF-B769-7461A95432DC

Q37644483-3089E883-6793-4CB3-A569-6E5AA2D4363B

Q37644483-41E208EA-FD93-48E6-A378-3F41B2F2E7A4

Q37644483-6E867B17-DF49-41AB-BFCB-338F6FFF2A19

Q37644483-830ADCB3-059A-471F-A716-A15CD68D3A55

Q37644483-8664189F-BF33-46FD-82E4-FF10C83D0AE1

Q37644483-AA0328FE-4560-4A87-A565-5B8A9EE8BE8E

P2860

Q37644483-03BE47C7-7363-4282-8FD3-D56B8F44AB3D

Q37644483-08CCCC60-5C75-4556-95F0-B85B1D0DC540

Q37644483-0BD4622D-59CB-454D-961B-F234DA2BEAE6

Q37644483-23F223E5-9C0A-4B41-8135-B41AB20FAFDE

Q37644483-2AA5EAB8-4A06-4E51-9C9C-654A24295EAA

Q37644483-30C78224-89E8-47DA-B05E-25B21A1A7964

Q37644483-384DA00F-2F06-4389-9ED4-23CC7C861C76

Q37644483-49756A11-F429-4848-9C97-1568679B9742

Q37644483-4D0B22EC-188D-4747-B8D8-B84592162859

Q37644483-55841309-A2F9-4094-9095-F354C391613A

P2888

Q37644483-37E95CF5-FAF5-4994-A209-5D781D24CF95

P304

Q37644483-00E9779C-3AD5-4ED6-829A-65BD489B0CA9

P31

Q37644483-DDEAF634-2514-4A69-A145-CFF85365C697

P356

Q37644483-42766A9A-383C-4F2C-A885-4A185D1288FA

P407

Q37644483-26F98A9C-1D8F-4752-BC9C-5505A333E9DE

P433

Q37644483-ADB1488A-F7D4-49F1-AEC1-D2FF44E7E58C

P478

Q37644483-43F54B85-23C7-4F81-AB87-17C0C27F8EB0

P577

Q37644483-F7447582-BA59-4EB2-81C1-9183EC18BBF1

P698

Q37644483-6298BCAB-6EA6-437A-8258-0F2CECC99BDE

P921

Q37644483-C9833714-4912-4360-9B0C-2302C28F915D

P932

Q37644483-328DCCC6-8356-415A-ACEF-38844DE71503

P356

P1433

Neuropsychopharmacology

P1476

Adjunctive Lanicemine (AZD6765 ...... zed, Placebo-Controlled Study.

@en

P2093

Arif Khan

http://www.w3.org/2001/XMLSchema#string

Gerard Sanacora

http://www.w3.org/2001/XMLSchema#string

Hong-Lin Su

http://www.w3.org/2001/XMLSchema#string

Joel A Posener

http://www.w3.org/2001/XMLSchema#string

John M Zajecka

http://www.w3.org/2001/XMLSchema#string

Juan P Schronen

http://www.w3.org/2001/XMLSchema#string

Khanh H Bui

http://www.w3.org/2001/XMLSchema#string

Luis Barra

http://www.w3.org/2001/XMLSchema#string

Michael A Burke

http://www.w3.org/2001/XMLSchema#string

Michael C Quirk

http://www.w3.org/2001/XMLSchema#string

P2860

Antidepressant drug effects and depression severity: a patient-level meta-analysis

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects.

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.

Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.

P2888

P304

844-853

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2016.224

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27681442

http://www.w3.org/2001/XMLSchema#string

P921

P932

5312066

http://www.w3.org/2001/XMLSchema#string